Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland.
Perez-Saez J, Lauer SA, Kaiser L, Regard S, Delaporte E, Guessous I, Stringhini S, Azman AS; Serocov-POP Study Group. Perez-Saez J, et al. Among authors: kaiser l. Lancet Infect Dis. 2021 Apr;21(4):e69-e70. doi: 10.1016/S1473-3099(20)30584-3. Epub 2020 Jul 14. Lancet Infect Dis. 2021. PMID: 32679085 Free PMC article. No abstract available.
A patient with HIV-1 superinfection.
Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, Autran B, Goh LE, Perrin L. Jost S, et al. Among authors: kaiser l. N Engl J Med. 2002 Sep 5;347(10):731-6. doi: 10.1056/NEJMoa020263. N Engl J Med. 2002. PMID: 12213944 Free article. No abstract available.
Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report.
Schibler M, Vetter P, Cherpillod P, Petty TJ, Cordey S, Vieille G, Yerly S, Siegrist CA, Samii K, Dayer JA, Docquier M, Zdobnov EM, Simpson AJH, Rees PSC, Sarria FB, Gasche Y, Chappuis F, Iten A, Pittet D, Pugin J, Kaiser L. Schibler M, et al. Among authors: kaiser l. Lancet Infect Dis. 2015 Sep;15(9):1034-1040. doi: 10.1016/S1473-3099(15)00229-7. Epub 2015 Jul 19. Lancet Infect Dis. 2015. PMID: 26201298
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium. Huttner A, et al. Among authors: kaiser l. Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4. Lancet Infect Dis. 2015. PMID: 26248510 Free PMC article. Clinical Trial.
1,548 results